| Title: |
Remdesivir treatment for patients with moderate to severe COVID-19 |
| Authors: |
Alp, Emine; Gül, Ahmet; Tabak, Fehmi; Erdinç, Şebnem; Ünal, Serhat; Çağatay, Arif Atahan; Pullukçu, Hüsnü; Çelikbaş, Aysel; Karaali, Ridvan; Kazak, Esra; Şenoğlu, Sevtap; Yaşar, Kadriye Kart; Bozkurt, Ilkay; Sevgi, Dilek Yildiz; Eren, Esma; Dizman, Gülçin Telli; Batirel, Ayşe; Kanat, Fikret; Çelik, Ilhami; Güner, Rahmet; HASANOĞLU, İMRAN |
| Publication Year: |
2022 |
| Description: |
© TÜBİTAK.Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.55730/1300-0144.5387 |
| Availability: |
https://doi.org/10.55730/1300-0144.5387; https://avesis.kayseri.edu.tr/publication/details/3d334c46-090c-4756-831a-41c821b37654/oai |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.80AAAA5E |
| Database: |
BASE |